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Abstract
The aim of the study was to validate the impact of the single-nucleotide polymorphism rs2413739 (T > C) in the PACSIN2
gene on thiopurines pharmacological parameters and clinical response in an Italian cohort of pediatric patients with acute
lymphoblastic leukemia (ALL) and inflammatory bowel disease (IBD). In ALL, PACSIN2 rs2413739 T allele was associated
with a significant reduction of TPMT activity in erythrocytes (p= 0.0094, linear mixed-effect model, multivariate analysis
considering TPMT genotype) and increased severe gastrointestinal toxicity during consolidation therapy (p= 0.049). A
similar trend was present also for severe hematological toxicity during maintenance. In IBD, no significant effect of
rs2413739 could be found on TPMT activity, however azathioprine effectiveness was reduced in patients carrying the T
allele (linear mixed effect, p= 0.0058). In PBMC from healthy donors, a positive correlation between PACSIN2 and TPMT
protein concentration could be detected (linear mixed effect, p= 0.045). These results support the role of PACSIN2
polymorphism on TPMT activity and mercaptopurine adverse effects in patients with ALL. Further evidence on PBMC and
pediatric patients with IBD supports an association between PACSIN2 variants, TPMT activity, and thiopurines effects, even
if more studies are needed since some of these effects may be tissue specific.
Introduction
Thiopurines, such as 6-thioguanine (TG), mercaptopurine
(MP), and its prodrug azathioprine (AZA), are the key drugs
used in the treatment of several pediatric diseases, including
acute lymphoblastic leukemia (ALL) and inflammatory
bowel disease (IBD). These agents exert their therapeutic
effects in lymphoid cells by acting as antimetabolites:
mimicking the structure of purines, they are converted to
thioguanine nucleotide analogs [TGN, meant as the set of
all derivatives: thioguanosine mono-, di-, tri-phosphate
(tGMP, tGDP, tGTP) and deoxythioguanosine mono-, di-,
tri-phosphate (tdGMP, tdGDP, tdGTP)]. TGN are in turn
able to interfere with cellular processes: the incorporation of
tdGTP into DNA and of tGTP into RNA damages nucleic
acids, impairs DNA replication and DNA repair machi-
neries, thus resulting in cell-cycle arrest and apoptosis [1].
The inhibition of the purine de novo synthesis pathway and
tGTP-mediated inhibition of the Rho-GTPase Rac1 repre-
sents additional mechanisms of action that potentiate the
antiproliferative effects of thiopurines in lymphocytes [1].
The thiol moiety of thiopurines, either as free bases or in
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nucleotide form, is substrate of thiopurine methyl transfer-
ase (TPMT; EC 2.1.1.67) and the generation of the S-
methylated derivatives (MMPN) competes with TGN pro-
duction. Changes in TPMT activity may affect TGN and
MMPN levels, and may therefore account for the inter-
individual differences in therapeutic response or toxicities
observed after thiopurine administration. Indeed, TGN
levels above 235 pmol/8 × 108 red blood cells (RBC) are
required for the therapeutic effect in IBD patients [2];
however, higher concentration of TGN (>400 pmol/8 × 108
RBC) can strongly suppress hematopoiesis, leading to
severe hematological (HEM) complications (anemia,
bleeding, leukopenia, and infections (INF)). In patients with
ALL, some clinical protocols suggest MP dose reduction
with TGN concentration above 1000 pmol/8 × 108 RBC in
order to avoid excessive toxicity [3]. The role of MMPN is
controversial: levels above 5700 pmol/8 × 108 RBC have
been associated with hepatotoxicity [2, 4]; a contribution to
the cytotoxic and immunosuppressive effects of thiopurines,
through inhibition of de novo ATP and GTP synthesis, has
been postulated for S-methyl-thioinosine monophosphate, a
component of MMPN [1].
In Caucasians, ~90–95% of subjects have a normal/high
TPMT methylating activity, whereas 5–10% show a
reduced and ~0.5% a completely abolished enzymatic
activity [5–8]. A strong genotype–phenotype correlation
explains the trimodal distribution of TPMT activity: three
well-characterized nonsynonymous single-nucleotide poly-
morphisms (SNPs rs1142345, rs1800460 and rs1800462) in
the TPMT gene account for more than 95% of TPMT
deficiency, with 10% of the population being heterozygous
for at least one of them and 0.3% carrying the homozygous-
variant genotype responsible for complete protein loss and
lack of function [9]. TGN toxic levels are observed in
TPMT-deficient patients treated with standard doses of
thiopurines [10]. The US Food and Drug Administration
and the European Medicines Agency recommend geno-
typing TPMT SNPs prior to thiopurine administration in
order to optimize therapy, without affecting treatment effi-
cacy [11]. Guidelines for thiopurine dose adjustment based
on TPMT genotype/phenotype have been published by
several cooperative groups, including the Clinical Pharma-
cogenetics Implementation Consortium [10, 12], the Dutch
Pharmacogenetic Working Group (https://www.knmp.nl/
downloads/pharmacogenetic-recommendations-november-
2018.pdf), and others [13].
In 2011, Stocco et al. identified PACSIN2 (Protein kinase
C and casein kinase II interacting protein-2 or Syndapin 2)
and its intronic SNP rs2413739 (T > C) as the most important
trans-acting gene and genetic variant influencing TPMT
activity by gene expression and genome-wide analyses on a
panel of 30 human HapMap cell lines trios [14]. In ALL
patients enrolled in the Total 13B/15 protocols at St. Jude
Children’s Research Hospital (SJCRH, Memphis, TN), the
PACSIN2 rs2413739 TT genotype was associated with lower
TPMT activity during maintenance therapy and with an
increased incidence of grade III–IV gastrointestinal (GI)
toxicities during the consolidation phase. This latter result
was also validated in the independent ALL cohort of children
enrolled in the AIEOP-BFM (Associazione Italiana Emato-
logia Oncologia Pediatrica–Berlin–Frankfurt-Münster) ALL
2000 protocol [14]. Human PACSIN2 encodes for a ubiqui-
tously expressed protein containing an F-BAR-domain at its
N-terminus and an Src homology-3 (SH3)-domain at the
C-terminus. F-BAR proteins are the most important reg-
ulators of membrane curvature and activate distinct signaling
pathways by specific domain-binding partners [15, 16]. In
particular, PACSIN2 is involved in vesicle trafficking [16], in
regulating the formation and scission of caveolae [17, 18],
and in promoting microtubule assembly [16, 19]. Interest-
ingly, PACSIN2 SH3 domain directly interacts with Rac1, a
molecular therapeutic target of thiopurines as demonstrated
by in vitro studies and in adult IBD patients. [16, 20–22]
These data provide the rationale for considering PACSIN2
as a potential biomarker of thiopurine effectiveness and
toxicities.
The present study was aimed to characterize more deeply
the impact of PACSIN2 SNP rs2413739 on thiopurine
pharmacokinetic and pharmacodynamic parameters in
children, either ALL patients treated with the AIEOP-BFM
2009 protocol or IBD patients undergoing AZA therapy.
Moreover, the role of this polymorphism on TPMT and
PACSIN2 protein concentration was evaluated for the first
time to authorsʼ knowledge in an exploratory way in adult
healthy donors.
Methods
Study design and populations
MP pharmacological parameters were measured in two
independent pediatric patients' cohorts. The first consisted
of 280 patients that were newly diagnosed with Philadelphia
chromosome-negative ALL at the Hemato-oncological
Units of the Pediatric Hospitals IRCCS “Burlo Garofolo”
in Trieste (n= 46, 16.4%), “Regina Margherita” in Turin
(n= 75, 26.8%), “Centro Maria Letizia Verga” in Monza
(n= 86, 31.0%), and “Bambino Gesù” in Rome (n= 73,
26.1%). Patients (median (interquartile range, IQ) age: 4.8
(3.0–9.2) years; male: 54.9%) were treated according to the
AIEOP-BFM ALL 2009 protocol (ClinicalTrials.gov iden-
tifier: NCT01117441, http://clinicaltrials.gov). Biological
materials were sent at 4 °C to the Department of Life Sci-
ences of the University of Trieste and processed within 24 h
since shipment. Bone marrow aspirates were collected at
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diagnosis and processed for pharmacodynamic analysis. For
pharmacokinetic analysis, peripheral blood samples were
collected in EDTA during the consolidation phase, which
consisted of daily MP (25 mg/m2 per os) and biweekly
high-dose methotrexate (MTX, 5 g/m2/dose i.v.), just before
the fourth and last biweekly infusion. During the main-
tenance phase with daily MP (50 mg/m2 per os) and weekly
low-dose MTX (20 mg/m2 per os), blood samples were
planned to be collected at the scheduled visits on the 3rd,
9th and 15th month.
The second cohort consisted of 119 patients affected by
IBD (median age (IQ): 15.1 (12.3–16.9) years; male:
52.1%) enrolled at the Gastroenterology Unit of the IRCCS
“Burlo Garofolo” in Trieste, Italy. Sixty-seven of these
patients (56.3%) were affected by Crohn’s disease (CD),
fifty-one (42.9%) by ulcerative colitis (UC), and one (0.8%)
by indeterminate colitis. IBD patients had been treated with
daily weight-based AZA therapy for at least 3 months
before enrollment (median dose (IQ): 2.0 (1.7–2.3) mg/kg/
die per os; median treatment length (IQ): 493.5
(231.5–897.5) days). Peripheral blood samples, antic-
oagulated with EDTA and immediately added with 1 mg of
the antioxidant dithiothreitol (DTT, Sigma-Aldrich, Milan,
Italy) to preserve the free thiol moiety of thiopurines, were
collected at scheduled control visits and used for pharma-
cogenetic and pharmacokinetic analysis. These blood sam-
ples were also sent at 4 °C to the University of Trieste and
processed within 24 h. An overview of the study design,
highlighting samples collected and pharmacological ana-
lyses performed in both cohorts, is given in Supplementary
Fig. 1.
Buffy coats of 20 healthy blood donors (median age (IQ):
47 (35.8–57) years; male: 70%) were provided by the
Department of Transfusion Medicine, Azienda Ospedaliera
Universitaria of Trieste (Italy). Blood was obtained by
venepuncture and immediately processed. A total of 4 ml of
each buffy coat was used for the isolation of peripheral blood
mononuclear cells (PBMC) and for DNA extraction and
genotyping as well as for preparing protein lysates for
western blot.
The clinical studies were approved by the local ethical
committees and appropriate informed consent was obtained
from patients/donors and/or their parents or guardians.
DNA extraction and pharmacogenetic analysis
Total genomic DNA was isolated from patient peripheral
blood and healthy donor buffy coats using a commercial kit
(Sigma-Aldrich, Milan, Italy) according to the manu-
facturer’s protocol. TaqMan® SNP genotyping assays
(Applied Biosystems, USA) were used to characterize the
SNPs of interest (TPMT rs1142345, rs1800460 and
rs1800462 and PACSIN2 rs2413739, Table 1). Samplesʼ
genotyping was repeated twice.
Pharmacokinetic analysis
Measurement of thiopurine metabolites in patients’ RBC
Thiopurine metabolites were quantified using a previously
described method [23] and results were expressed as pmol/
8 × 108 RBC. A brief description of the method is reported
in Supplementary Material.
TPMT activity in patients’ RBC
TPMT activity was measured as previously described [24],
and results were expressed as nmoles of methyl-mercapto-
purine produced in 1 h per 106 RBC (nmol 6-MMP/h/1 ×
106 RBC). A brief description of the method is reported in
Supplementary Material.
Pharmacodynamic analysis: blasts in vitro sensitivity to
thiopurines
The in vitro effect of thiopurines on ALL blasts was
evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide-based viability assay, as previously
described [25]. Nonlinear regression of dose–response data
was performed computing IC50, the drug concentration
required to reduce viability to 50%. Imax was also calculated
from the dose–response curve and defined as the percentage
of cell death achieved with the highest drug concentration
tested (3.0 × 10–4 M for TG and 3.0 × 10−3M for MP). A
brief description of the method is reported in Supplementary
Material.
PBMC isolation and western blotting
PBMC were collected by density gradient centrifugation
and western blotting analysis was performed as described in
the Supplementary Material.
Clinical response
Clinical data were collected by pediatricians blinded to results
of pharmacological analysis and according to routine clinical
practice. For ALL patients, episodes of INF, GI, pancreatic/
hepatic (PAN/HEP), renal (REN), cardiologic (CARDIO),
neurological (NEU), and HEM toxicity during consolidation
and maintenance phases were graded referring to a simplified
version of the National Cancer Institute-Common Terminol-
ogy Criteria scales (Supplementary Table S1). Clinical data
were available only for a small subset of ALL patients (81
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children in consolidation and 47 in maintenance), being still
under collection for the others.
Clinical efficacy was assessed in patients with IBD,
using Pediatric Crohn’s Disease Activity Index (PCDAI)
and Pediatric Ulcerative Colitis Activity Index (PUCAI) for
CD and UC patients, respectively, at the time of blood
sample collection for the metabolites’ measurement
[26, 27]. Disease was considered inactive if indexes were
lower than 10 at the time of sample collection.
Statistical analysis
Statistical analyses were performed using the software R
(version 3.4.2).
The association between pharmacological parameters
(pharmacokinetic and pharmacodynamic, dependent variable)
and pharmacogenomic variables (independent variables) was
examined using linear mixed-effect models of the Gaussian
family. The effect of gender and age covariates was also
examined. In patients with IBD, to study disease activity,
linear mixed-effect models of the binomial family were used,
considering disease activity as the dependent variable and the
pharmacogenomic variables as the independent variables. The
mixed effects models were built using the phenotype of
interest as the dependent variable, each covariate as the fixed
effect and the patients as the random effect in the model. In
pharmacokinetic analysis, TGN levels below 50 pmol/8 × 108
RBC were excluded. In patients with ALL, toxicities were
separately considered: each was dichotomized as severe
(grade III/IV) versus nonsevere (grade I/II or absent), without
discriminating among specific adverse episodes. Logistic
regression model was used to assess the effect of genotypes
on the onset of severe toxicity. All pharmacogenomic ana-
lyses evaluated an additive effect of the genotype on the
phenotype of interest. For the study on healthy donor blood
samples, the association between TPMT, PACSIN2 protein
concentration, PACSIN2 polymorphism was evaluated by
mixed-effect linear models. Since our study is a validation
study focused on few comparisons, the standard significance
threshold of 0.05 was applied to p values and no multiple
testing adjustment was performed [28]. Normality of the
phenotype was tested by the Shapiro test and appropriate
transformation was applied if needed, in order to adjust the
normality of the distribution.
Results
PACSIN2 and TPMT genotype distribution in
patients’ cohorts
Three SNPs in the TPMT gene (rs1142345, rs1800460, and
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genotyped in ALL and IBD in pediatric patients: results are
shown in Table 1. The two cohorts were similar in TPMT
genotype distribution, with ~5% of patients carrying the low-
activity TPMT alleles in both populations, as expected from
previously published data in Caucasians and in ALL Italian
children [8, 12]. Patients with a variant TPMT allele were all
heterozygous TPMT*3A (haplotype rs1142345 and
rs1800460), with the exception of one heterozygous
TPMT*3C (rs1142345) ALL patient: none of them carried the
TPMT*2 (rs1800462) allele and none was homozygote for the
variant alleles. Similarly, no significant difference in PAC-
SIN2 SNP rs2413739 genotype distribution was observed
between ALL and IBD children, with ~40% of them carrying
the TC genotype and ~30% being TT, as expected for Cau-
casian [14]. Genotype frequencies were in Hardy–Weinberg
equilibrium (HWE, p > 0.05) in both cohorts.
PACSIN2 rs2413739 and thiopurine
pharmacokinetics
TPMT enzymatic activity
The influence of demographic characteristics on TPMT
enzymatic activity was evaluated in pediatric patients under-
going a long-term, thiopurine-based therapy. Interestingly, the
enzymatic function was significantly higher in ALL patients
compared with IBD patients (p= 0.032, linear mixed-effect
model). In both cohorts, TPMT activity was not influenced by
age and gender (Supplementary Table S2).
For the genetic analysis, TPMT genotype was available
for all patients with at least one measurement of TPMT
enzymatic activity, while PACSIN2 genotype was
available for 23 IBD and 89 ALL patients, respectively
(Fig. 1). In IBD, no significant difference in TPMT
activity was observed among the PACSIN2 rs2413739 TT
(six patients, 26.1%), TC (eight, 34.8%), and CC (nine,
39.1%) subjects (p= 0.73, linear mixed-effect model,
Fig. 1a); these children were all TPMT wild type. In ALL,
univariate analysis demonstrated that TPMT activity was
significantly reduced in TPMT heterozygotes (rs1142345
and rs1800460, linear mixed-effect model, p < 10−4) and
in the presence of the PACSIN2 rs2413739 T allele (linear
mixed-effect model, p= 0.0013). Genotype effects
remained statistically significant after multivariate analy-
sis considering both genes (TPMT rs1142345, p= 10−4;
PACSIN2 rs2413739, p= 0.0094, Fig. 1b, TPMT geno-
type explaining 16,7% of variability in the TPMT activity
and PACSIN2 genotype 9.6%). Interestingly, PACSIN2
genotype effect was particularly evident within TPMT
heterozygotes (linear mixed-effect model, p= 0.040) in
comparison with TPMT wild type patients (linear mixed-
effect model, p= 0.044).
Thiopurine metabolites
Table 2 summarizes the TGN and MMPN levels in the two
pediatric cohorts. In ALL patients, a direct correlation was
found between age and metabolites: TGN were significantly
higher in adolescent in comparison with younger patients in
maintenance. Statistical significance was not reached for
MMPN; however, a tendency towards higher MMPN con-
centration in teenagers was observed in maintenance.
Metabolites did not differ between male and female patients
in either cohort (Table 2).
Fig. 1 Correlation between TPMT enzymatic activity and TPMT
rs1142345 and PACSIN2 rs2413739 genotypes in a subgroup of
(a) IBD patients and (b) ALL patients. Blood samples of ALL patients
were collected during maintenance. Each point represents the median
value for the variable considered for each patient. p values were cal-
culated by the linear mixed-effect model, *p= 0.0094 for PACSIN2
rs2413739 according to the multivariate analysis including TPMT
genotypes
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Among ALL patients, the presence of a TPMT low-
activity allele increased the concentration of TGN (linear
mixed-effect model, p < 10−4) and decreased that of MMPN
(linear mixed-effect model, p= 0.0003) in patients’ RBC
during the maintenance phase (thiopurine metabolites
measured in 232 blood samples of 131 children). By con-
trast, PACSIN2 rs2413739 did not affect metabolites levels
(239 blood samples of 137 children analyzed). Similar
results were observed in samples obtained during the con-
solidation phase (increased TGN (linear mixed-effect
model, p= 10−4) and decreased MMPN concentrations
(linear mixed-effect model, p= 0.047) for TPMT hetero-
zygotes, no genetic effect of PACSIN2 rs2413739, thio-
purine metabolites measured in 113 children).
Among IBD patients, TPMT genotype was known for
112 children with thiopurine metabolites measured in 273
blood samples, and PACSIN2 genotype for 84 children with
thiopurine metabolites measured in 209 blood samples.
Heterozygous TPMT*3A patients showed an increased
value of TGN (linear mixed-effect model, p= 0.0039) and a
significant reduction in MMPN (linear mixed-effect model,
p= 0.0011) with respect to wild type TPMT subjects;
PACSIN2 rs2413739 did not affect TGN and MMPN levels.
PACSIN2 rs2413739 and ALL patients’ thiopurine
pharmacodynamics
The pharmacodynamic assay with TG and MP was per-
formed on blasts isolated from bone marrow aspirates of
39 and 31 ALL patients, respectively (Supplementary
Material). Patients age did not affect blasts in vitro sensi-
tivity, whereas a gender effect was observed for MP:
females showed a higher resistance to MP in comparison
with males (linear model, p= 0.033). All patients were wild
type for TPMT. The correlation between thiopurine in vitro
sensitivity and PACSIN2 rs2413739 polymorphism was
also investigated but no difference according to genotype
was found.
PACSIN2 rs2413739 and clinical response
Out of 212 ALL patients with known PACSIN2 rs2413739
genotype, toxicities data were available for 81 children in
consolidation and 47 in maintenance. During consolidation,
the incidence of severe (grade ≥ 3) adverse effects were:
HEM 48.1%, GI 9.9%, INF 4.9%, PAN/HEP 3.7%, REN
1.2%, CARDIO 0%, NEU 0%; during maintenance, the
incidence was: HEM 65.9%, PAN/HEP 19.1%, INF 14.9%,
GI 8.5%, CARDIO 2.1 %, REN 0%, NEU 0%. Borderline
significance emerged for PACSIN2 SNP rs2413739 and GI
during consolidation, with an increased risk of adverse
effect in TT carriers (linear mixed effects p= 0.04947,
Table 3), and a similar trend was observed also for HEM
toxicity during maintenance (p= 0.0998).
All IBD patients had been treated continuously with
daily weight-based oral AZA therapy for at least 3 months
before enrollment (median dose (interquartile range, IQ):
2.0 (1.7–2.3) mg/kg/die; median (IQ) treatment length:
493.5 (231.5–897.5) days). Clinical response to AZA
therapy was evaluated in 78 patients (180 samples
Table 2 Thiopurine metabolites in patients’ RBC and association with demographic characteristics
IBD cohort ALL cohort
Consolidation Maintenance*




















Age (p value) 0.39 0.17 0.15 0.93 0.03 0.09
Gender (p value) 0.41 0.92 0.21 0.83 0.26 0.38
TPMT variants
(p value)




0.40 0.76 0.37 0.35 0.58 0.61
ALL acute lymphoblastic leukemia, IBD inflammatory bowel disease, IQ interquartile range, MMPN methylmercaptopurine nucleotides, RBC red
blood cells, TGN thioguanine nucleotides
*Multiple measurements over time (3rd, 9th, and 15th months) were reported for 74 patients (n= 3, 28 patients; n= 2, 46 patients): in these
patients, the mean values of TGN and MMPN were considered
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analyzed): AZA effectiveness was reduced in children
carrying the T allele of the SNP rs2413739 (linear mixed
effects, p= 0.0058; genotyping results: CC in 22, CT in
33, and TT in 23 patients): indeed, a clinically active
disease was observed in 43.1% of TT patients, in 28.4% of
those with the CT genotype and in 18.2% of the CC
subjects (Fig. 2). TPMT variant genotype, present in 2 of
the 78 patients as TPMT*3A heterozygous allele, was not
significantly associated with AZA effectiveness.
TPMT and PACSIN2 variants in healthy donors’
PBMC
To evaluate the role of PACSIN2 SNP rs2413739 on
TPMT and PACSIN2 protein level, 20 adult healthy
donors were genotyped for the SNPs of interest, and
western blot analysis of human TPMT and human PAC-
SIN2 was performed on their PBMCs lysates. Only one of
the volunteers was heterozygous for TPMT*3A; the gen-
otype distribution of PACSIN2 rs2413739, with six (30%)
heterozygous and seven (35%) carrying the TT wild-type
genotype, was not in HWE likely because of the small
number of individuals considered. In the lysates, TPMT
showed a protein concentration that was approximately the
double of that measured for PACSIN2 (median (IQ): 77.3
(64.7–93.8)% versus 38.9 (26.9–65.1)%, respectively).
(Supplementary Fig. 2). No significant contribution of the
polymorphism was found on TPMT and PACSIN2 protein




































































































































































































































































































































































































































































Fig. 2 Disease activity and PACSIN2 rs2413739 genotypes in IBD
patients. Bar plots represent the percentage of patients in remission
(gray) and with active disease (black) according to PACSIN2
rs2413739 genotype. Clinically active disease was assessed as PCDAI
and PUCAI values above 10. Disease activity was assessed at the time
of the measurement of thiopurine metabolites. One hundred and eighty
observations in seventy-eight patients were considered. p value was
calculated by the linear mixed-effect model of the binomial family
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direct correlation between the TPMT and PACSIN2 levels
was observed (linear mixed effect, p= 0.045, conditional r2
= 64%, Fig. 3), suggesting a putative coordination in their
protein levels.
Discussion
Our data document that PACSIN2 rs2413739 T allele reduces
the TPMT enzymatic activity during the MP/MTX-based
maintenance therapy of the AIEOP-BFM ALL 2009 protocol
but not in the AZA-based IBD therapy, although no SNP
effect was observed on metabolite levels. The role of PAC-
SIN2 rs2413739 on the TPMT enzymatic activity in ALL
was first proposed in 2012 in a SJCRH cohort [14], and has
been validated in multivariate analysis in the AIEOP-BFM
ALL 2009 protocol; the present study confirms also the
expected contribution of TPMT SNPs rs1142345 and
rs1800460 on the TPMT phenotype. Recent genome-wide
association studies (GWAS) have not confirmed the PAC-
SIN2 rs2413739 effect and have provided strong evidence
of TPMT as the only monogenic trait influencing the TPMT
phenotype, finding that only TPMT variants are significantly
associated with TPMT activity in ALL children (n= 1026;
p= 8.6 × 10−61) [29] and in a mixed population (two
cohorts of adult healthy volunteers and one of pediatric
ALL patients, n= 1212; p= 1.2 × 10−72) [30]. We hypo-
thesized that the discrepancy on the PACSIN2 rs2413739
results could be linked to the different times used for RBC
sampling, likely due to the greater level of TPMT in newly
synthesized erythrocytes [31]. Indeed, in both GWAS,
TPMT activity has been measured after induction, a ther-
apeutic phase that causes profound myelosuppression and is
followed by bone marrow cellular recovery, whereas in the
present study the enzyme activity has been assessed during
maintenance, in a therapeutic phase when RBC have
already undergone a progressive ageing process and mye-
losuppression is less severe. Moreover, GWAS studies may
detect more easily strong effects, while smaller ones may be
more difficult to reproduce [32]. Concomitant drugs repre-
sent an alternative hypothesis to explain the discrepant
PACSIN2 rs2413739 results in ALL: MTX, co-administered
with MP across all AIEOP-BFM ALL 2009 therapeutic
phases, is able to deplete S-adenosyl methionine, a TPMT
cofactor particularly important for the stability of the TPMT
protein [33]. It is therefore likely that the genetic effect of
PACSIN2 rs2413739 on TPMT activity in ALL children
emerges only under more physiological conditions, such as
those found during the maintenance phase characterized by
low-doses MTX and quite normal production and life cycle
of RBC. A recent study has associated the PACSIN2
rs2413739 genotypes with the incidence of HEM toxicities
during maintenance, this finding further supports the effect
of this polymorphism in thiopurine biotransformation dur-
ing this phase [34]. It is possible that the putative weak
genetic influence of PACSIN2 varies with patient age and
becomes more evident in younger patients because of
higher measurable TPMT activity [35]. Indeed, it has been
reported that TPMT activity is higher in infants in com-
parison with children [36] and in adolescents in comparison
with older patients and adults [37], although this age
dependence is controversial [14, 38]. This hypothesis could
explain the lack of PACSIN2 rs2413739 influence on TPMT
during the AZA-based maintenance immunosuppression in
IBD therapy, in contrast to what is observed in the MP/
MTX-based ALL treatment. Our IBD patients were all
teenagers with a median age of around 15 years, whereas
ALL patients were mostly children below 10 years of age.
Epigenetic mechanisms, such as the promoter methylation
of TPMT [39], could stand at the basis of age-related TPMT
function. It should be also noted that no direct effect of age
on TPMT activity was observed in neither ALL nor IBD
cohort, although an effect of age on TGN levels in the ALL
cohort (higher in adolescents compared with younger
patients) was found: this effect may dependent on the
activity of other enzymes and/or transporters involved in the
MP metabolizing pathway as well as on environmental and
clinical factors. Moreover, the number of TPMT enzymatic
measurements in the IBD group was very limited and thus
further studies need to be performed to shed light on the
contribution of age in thiopurine pharmacokinetics.
Fig. 3 Association between TPMT and PACSIN2 protein concentra-
tions evaluated by western blotting in PBMC cellular extracts from
adult healthy donors. Values were normalized by logarithmic trans-
formation (for PACSIN2 concentration) or square root (for TPMT
concentration). Each black point represents the average of the two
quantifications performed for each cell extract. White circles represent
the predicted PACSIN2 concentration values based on TPMT values,
from the mixed-effect linear model built on the basis of these mea-
surements (p= 0.045)
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For ALL patients, an increased incidence of grade III/IV
stomatitis and diarrhea during consolidation therapy in
patients with variant T alleles could be confirmed, as pre-
viously reported [14]. Moreover, a trend for an association
between PACSIN2 variants and severe HEM toxicities
during maintenance therapy was found, confirming pre-
viously described data [34]. The results showed in this
study are encouraging toward a significant effect of PAC-
SIN2 variant on chemotherapy-induced adverse events
occurrence although they are limited by the small number of
individuals with already available clinical data. Pharmaco-
logical analyses should be associated to the clinical outcome
in the whole ALL cohort before drawing definitive con-
clusions, and should be interpreted carefully considering
also potential underlying confounding variables, such as
relevant clinical information (e.g., immunophenotype,
variables of treatment response including minimal residual
disease, treatment risk groups).
In the IBD cohort, an increased disease activity has been
observed for carriers of PACSIN2 rs2413739 TT genotype.
This could be at least partly interpreted as resistance to the
thiopurine antimetabolite AZA and could be a TPMT-
independent effect, possibly related to phenomena, such as
modulation of autophagy or other tissue-specific effects
[14]. Due to the low incidence of events, none of which had
grade III or IV severity, toxicities were not considered in the
analysis for this cohort.
These preliminary clinical results, together with the
observation that PACSIN2 SNP does not influence the MP
metabolite levels in any of the two analyzed cohorts, sug-
gest that thiopurine pharmacokinetics is a complex trait,
probably influenced by multiple genes and nongenetic
factors. However, it can also be hypothesized that PACSIN2
rs2413739 could have some TPMT-independent tissue-
specific effect on thiopurine cytotoxic effects, of particular
importance in the gastrointestinal tract. Indeed, rs2413739
polymorphism shows a different tissue-specific gene
expression pattern between whole blood and the colon-
sigma, as reported for larger cohorts in the public available
genotype-tissue expression (GTEx) portal (www.gtexportal.
org). GTEx reports a higher PACSIN2 expression in sub-
jects carrying the rs2413739 T allele in blood (p= 10−11)
but not in colon-sigma (p= 0.9). Moreover, TT carriers
have also a higher TPMT expression in the former tissue
(p= 0.006 versus p= 0.23). In this study, the polymorph-
ism was not associated with PACSIN2 and TPMT protein
concentrations, likely because of the small number of
healthy donors analyzed.
This study has some limitations. A small number of
samples were considered in some of the subgroups, there-
fore some of the analyses (e.g: association of PACSIN2 SNP
and TPMT activity in IBD patients or association of PAC-
SIN2 SNP and chemotherapy cytotoxic effects in ALL
patients, as already mentioned) can have low statistical
power and requires further investigations in larger cohorts.
Being a validation study, no formal power analysis was
performed. In this study, no adjustment was done for mul-
tiple comparisons; the use of multiple comparison in
studying few candidate SNPs in relation to a given phe-
notype is debated [40], and indeed this study focuses on
only few comparisons that comprise two candidate poly-
morphisms and the standard demographic covariates age
and gender. Adjusting significance threshold beyond stan-
dard values seemed over conservative to authors also
because, being a validation study on the role of PACSIN2
SNP on pharmacokinetic parameters, our significant results
are strengthened by the coherence with previous evidence.
In conclusion, this study addresses an important issue
related to the treatment of children with thiopurines either
for ALL or IBD and provides new insights on the role of
PACSIN2 on TPMT activity and protein that seems to be
dependent on the age and clinical condition of the patient.
Indeed, the study confirms this effect in children with ALL,
but not in teen patients with IBD. Moreover,
PACSIN2 seems to modulate thiopurines effect in the
gastrointestinal tract also in patients with IBD, since PAC-
SIN2 polymorphism was associated with AZA efficacy
measured as a clinical activity score below 10. Nonetheless,
these results have limited validity for clinicians as they are:
indeed, they are based on small numbers of individuals and
significance in clinical response is partly borderline. Further
studies are needed to fully elucidate the molecular
mechanism involved in the age and tissue specificity of the
association between PACSIN2, TPMT, and thiopurines
sensitivity in children needing these drugs.
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